Page 1038 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

62. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive 79. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the
insulin therapy protects the endothelium of critically ill patients. detection of sepsis in the critically ill burn patient: a systematic
J Clin Invest. 2005;115(8):2277-2286. review of the literature. Burns. 2011;37(4):549-558.
63. Vanhorebeek I, Van den Berghe G. The neuroendocrine 80. Tschaikowsky K, Hedwig-Geissing M, Braun GG, Radespiel-
response to critical illness is a dynamic process. Crit Care Clin. Troeger M. Predictive value of procalcitonin, interleukin-6, and
2006;22(1):1-15, v. C-reactive protein for survival in postoperative patients with
64. Hillenbrand A, Knippschild U, Weiss M, et al. Sepsis induced severe sepsis. J Crit Care. 2011;26(1):54-64.
changes of adipokines and cytokines - septic patients compared 81. Karlsson S, Heikkinen M, Pettila V, et al. Predictive value of pro-
to morbidly obese patients. BMC Surg. 2010;10:26. calcitonin decrease in patients with severe sepsis: a prospective
65. Goodman S, Sprung CL, Ziegler D, Weiss YG. Cortisol changes observational study. Crit Care. 2010;14(6):R205.
among patients with septic shock and the relationship to ICU 82. Baruti GZ, Pacarizi H, Zhubi B, Begolli L, Topciu V. The impor-
and hospital stay. Intensive Care Med. 2005;31(10):1362-1369. tance of determining procalcitonin and C reactive protein in
66. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk different stages of sepsis. Bosn J Basic Med Sci. 2010;10(1):60-64.
assessment in sepsis. Clin Chest Med. 2008;29(4):591-603, vii. 83. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalci-
67. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. tonin to shorten antibiotic treatment duration in septic patients: a
2010;14(1):R15. randomized trial. Am J Respir Crit Care Med. 2008;177(5):498-505.
68. Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. 84. Le Gall JR. The use of severity scores in the intensive care unit.
Interleukin-6 in surgery, trauma, and critical care part II: clinical Intensive Care Med. 2005;31(12):1618-1623.
implications. J Intensive Care Med. 2011;26(2):73-87. 85. Wagner DP, Knaus WA, Draper EA. Statistical valida-
69. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds tion of a severity of illness measure. Am J Public Health.
to apoptotic cells, protects the cells from assembly of the termi- 1983;73(8):878-884.
nal complement components, and sustains an antiinflammatory 86. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute
innate immune response: implications for systemic autoimmu- Physiology and Chronic Health Evaluation (APACHE) IV: hos-
nity. J Exp Med. 2000;192(9):1353-1364. pital mortality assessment for today’s critically ill patients. Crit
Care Med. 2006;34(5):1297-1310.
70. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D,
Sgarbi L. Procalcitonin and C-reactive protein during systemic 87. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute
inflammatory response syndrome, sepsis and organ dysfunction. Physiology Score (SAPS II) based on a European/North
Crit Care. 2004;8(4):R234-R242. American multicenter study. JAMA. 1993;270(24):2957-2963.
71. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, 88. Minne L, Abu-Hanna A, de JE. Evaluation of SOFA-based
Merlini A. Comparison of procalcitonin and C-reactive protein models for predicting mortality in the ICU: a systematic review.
as markers of sepsis. Crit Care Med. 2003;31(6):1737-1741. Crit Care. 2008;12(6):R161.
72. Lin CH, Yao M, Hsu SC, et al. Soluble triggering receptor 89. Higgins TL, Kramer AA, Nathanson BH, Copes W, Stark M,
expressed on myeloid cells-1 as an infection marker for patients Teres D. Prospective validation of the intensive care unit admis-
with neutropenic fever. Crit Care Med. 2011;39(5):993-999. sion Mortality Probability Model (MPM0-III). Crit Care Med.
2009;37(5):1619-1623.
73. Lin MT, Wei YF, Ku SC, Lin CA, Ho CC, Yu CJ. Serum soluble
triggering receptor expressed on myeloid cells-1 in acute respi- 90. Osman D, Ridel C, Ray P, et al. Cardiac filling pressures are not
ratory distress syndrome: a prospective observational cohort appropriate to predict hemodynamic response to volume chal-
study. J Formos Med Assoc. 2010;109(11):800-809. lenge. Crit Care Med. 2007;35(1):64-68.
74. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course 91. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis
of sTREM (soluble triggering receptor expressed on myeloid Campaign: international guidelines for management of severe
cells)-1, procalcitonin, and C-reactive protein plasma concen- sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.
trations during sepsis. Crit Care Med. 2005;33(4):792-796. 92. Reinhart K, Rudolph T, Bredle DL, Hannemann L, Cain SM.
75. Sarafidis K, Soubasi-Griva V, Piretzi K, et al. Diagnostic utility of Comparison of central-venous to mixed-venous oxygen satura-
elevated serum soluble triggering receptor expressed on myeloid tion during changes in oxygen supply/demand. Chest. 1989;
cells (sTREM)-1 in infected neonates. Intensive Care Med. 95(6):1216-1221.
2010;36(5):864-868. 93. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy
76. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. in the treatment of severe sepsis and septic shock. N Engl J Med.
Procalcitonin as a marker for the detection of bacteremia 2001;345(19):1368-1377.
and sepsis in the emergency department. Am J Clin Pathol. 94. Monnet X, Teboul JL. Passive leg raising. Intensive Care Med.
2011;135(2):182-189. 2008;34(4):659-663.
77. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, et al. 95. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in
Procalcitonin as an early indicator of outcome in sepsis: a pro- arterial waveform derived variables and fluid responsiveness
spective observational study. J Hosp Infect. 2011;77(1):58-63. in mechanically ventilated patients: a systematic review of the
78. Haasper C, Kalmbach M, Dikos GD, et al. Prognostic value literature. Crit Care Med. 2009;37(9):2642-2647.
of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma 96. Hofer CK, Senn A, Weibel L, Zollinger A. Assessment of
levels after multiple trauma for the development of multi organ stroke volume variation for prediction of fluid responsiveness
dysfunction syndrome (MODS) or sepsis. Technol Health Care. using the modified FloTrac and PiCCOplus system. Crit Care.
2010;18(2):89-100. 2008;12(3):R82.

Section05-O-ref.indd 3 1/20/2015 4:51:17 PM